Age-specific HPV type distribution in high-grade cervical disease in screened and unvaccinated women

被引:50
作者
Aro, Karoliina [1 ,2 ]
Nieminen, Pekka [1 ,2 ]
Louvanto, Karolina [1 ,2 ,4 ,5 ]
Jakobsson, Maija [1 ,2 ,6 ,7 ]
Virtanen, Seppo [1 ,2 ]
Lehtinen, Matti [3 ]
Dillner, Joakim [3 ]
Kalliala, Ilkka [1 ,2 ,8 ]
机构
[1] Univ Helsinki, Dept Obstet & Gynecol, Haartmaninkatu 2, FIN-00290 Helsinki, Finland
[2] Helsinki Univ Hosp, Haartmaninkatu 2, FIN-00290 Helsinki, Finland
[3] Karolinska Inst, Dept Lab Med, SE-17177 Stockholm, Sweden
[4] Turku Univ Hosp, Dept Obstet & Gynaecol, Kiinamyllynkatu 4-8, Turku 20521, Finland
[5] Univ Turku, Kiinamyllynkatu 4-8, Turku 20521, Finland
[6] Hyvinkaa Hosp Helsinki, Sairaalankatu 1, Hyvinkaa 05850, Finland
[7] Uusimaa Univ Hosp Dist, Sairaalankatu 1, Hyvinkaa 05850, Finland
[8] Imperial Coll, Inst Reprod & Dev Biol, Dept Surg & Canc, London SW7 2AZ, England
关键词
Squamous intraepithelial lesions of the cervix; Prevalence; HPV human papillomavirus; Genotype; PAPILLOMAVIRUS VACCINATION PROGRAM; INTRAEPITHELIAL NEOPLASIA; GENOTYPE DISTRIBUTION; PARTICLE VACCINE; HERD-IMMUNITY; DOUBLE-BLIND; FOLLOW-UP; CANCER; PREVALENCE; INFECTION;
D O I
10.1016/j.ygyno.2019.05.024
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and aim. Age-specific type-distribution of high-risk human papillomavirus (hrHPV) in cervical precancerous lesions is subject to change in the HPV vaccination era. Knowing the pre-vaccination type distribution helps to anticipate changes induced by mass vaccination and optimize screening. Methods. We recruited 1279 women referred to colposcopy for abnormal cytology into a population-based study on HPV type distribution in diagnostic cervical samples (ISRCTN10933736). The HPV genotyping findings were grouped as: HPV16/18+, other hrHPV+ (HPV31/33/35/39/45/51/52/56/58/59/66/68), non-vaccine targeted hrHPV+ (HPV35/39/51/56/59/66/68), low-risk HPV, and HPV negative. We estimated the HPV group-specific prevalence rates according to diagnostic histopathological findings in the age groups of <30 (n = 339), 30-44.9 (n = 614), and >= 45 (n = 326). Results. Altogether 503 cases with high grade squamous intraepithelial lesion or worse (HSIL+) were diagnosed. More than half, 285 (56.7%) of HSIL+ cases were associated with HPV16/18: 64.3% (101/157) in women <30 years (reference group), 58.4% (157/269) in women 30-44.9 years (risk ratio (RR) 0.91, 95% confidence interval (95% CI) 0.78-1.06), and 35.1% (27/77) in women >= 45 years of age (RR 0.55, 95% CI 039-0.75). Conversely, other hrHPV's were associated with 191 (38.0%) of HSIL+: 31.9% (50/157) in women <30, 36.8% (99/269) in women 30-44.9 years, 54.6% (42/77) and in women >= 45 (RR 1.71, 95% CI 126-2.33). The proportion of non-vaccine targeted hrHPV and HPV negative HSIL+ increased with advancing age. Conclusions. Pre-vaccination HPV type distribution in HSIL+ was distinctly polarised by age with HPV16/18 attributed disease being markedly more prevalent in women aged <30. In the older women the other hrHPV types, however, dominated suggesting a need for more age-dependent screening strategies. (C) 2019 The Authors. Published by Elsevier Inc.
引用
收藏
页码:354 / 359
页数:6
相关论文
共 40 条
[1]  
[Anonymous], BMJ
[2]  
[Anonymous], PAP TORJ SELV 2011
[3]  
[Anonymous], CYT CHANG CERV VAG V
[4]   Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors [J].
Arbyn, Marc ;
Xu, Lan ;
Simoens, Cindy ;
Martin-Hirsch, Pierre P. L. .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2018, (05)
[5]   Long-term Antibody Response to Human Papillomavirus Vaccines: Up to 12 Years of Follow-up in the Finnish Maternity Cohort [J].
Artemchuk, Hanna ;
Eriksson, Tiina ;
Poljak, Mario ;
Surcel, Helja-Marja ;
Dillner, Joakim ;
Lehtinen, Matti ;
Faust, Helena .
JOURNAL OF INFECTIOUS DISEASES, 2019, 219 (04) :582-589
[6]  
Bosch FX, 2008, VACCINE, V26, pV, DOI [10.1016/j.vaccine.2008.07.007, 10.1016/j.vaccine.2008.07.008, 10.1016/j.vaccine.2008.06.022]
[7]   Looking beyond human papillomavirus (HPV) genotype 16 and 18: Defining HPV genotype distribution in cervical cancers in Australia prior to vaccination [J].
Brotherton, Julia M. L. ;
Tabrizi, Sepehr N. ;
Phillips, Samuel ;
Pyman, Jan ;
Cornall, Alyssa M. ;
Lambie, Neil ;
Anderson, Lyndal ;
Cummings, Margaret ;
Payton, Diane ;
Scurry, James P. ;
Newman, Marsali ;
Sharma, Raghwa ;
Saville, Marion ;
Garland, Suzanne M. .
INTERNATIONAL JOURNAL OF CANCER, 2017, 141 (08) :1576-1584
[8]   The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV-Naive Women Aged 16-26 Years [J].
Brown, Darron R. ;
Kjaer, Susanne K. ;
Sigurdsson, Kristjan ;
Iversen, Ole-Erik ;
Hernandez-Avila, Mauricio ;
Wheeler, Cosette M. ;
Perez, Gonzalo ;
Koutsky, Laura A. ;
Tay, Eng Hseon ;
Garcia, Patricia ;
Ault, Kevin A. ;
Garland, Suzanne M. ;
Leodolter, Sepp ;
Olsson, Sven-Eric ;
Tang, Grace W. K. ;
Ferris, Daron G. ;
Paavonen, Jorma ;
Steben, Marc ;
Bosch, F. Xavier ;
Dillner, Joakim ;
Joura, Elmar A. ;
Kurman, Robert J. ;
Majewski, Slawomir ;
Munoz, Nubia ;
Myers, Evan R. ;
Villa, Luisa L. ;
Taddeo, Frank J. ;
Roberts, Christine ;
Tadesse, Amha ;
Bryan, Janine ;
Lupinacci, Lisa C. ;
Giacoletti, Katherine E. D. ;
Sings, Heather L. ;
James, Margaret ;
Hesley, Teresa M. ;
Barra, Eliav .
JOURNAL OF INFECTIOUS DISEASES, 2009, 199 (07) :926-935
[9]   Cervical Human Papillomavirus Prevalence in 5 Continents: Meta-Analysis of 1 Million Women with Normal Cytological Findings [J].
Bruni, Laia ;
Diaz, Mireia ;
Castellsague, Xavier ;
Ferrer, Elena ;
Bosch, F. Xavier ;
de Sanjose, Silvia .
JOURNAL OF INFECTIOUS DISEASES, 2010, 202 (12) :1789-1799
[10]   Human Papillomavirus Prevalence and Herd Immunity after Introduction of Vaccination Program, Scotland, 2009-2013 [J].
Cameron, Ross L. ;
Kavanagh, Kimberley ;
Pan, Jiafeng ;
Love, John ;
Cuschieri, Kate ;
Robertson, Chris ;
Ahmed, Syed ;
Palmer, Timothy ;
Pollock, Kevin G. J. .
EMERGING INFECTIOUS DISEASES, 2016, 22 (01) :56-64